Jason Yoho, MD
Interventional Cardiology · Seguin, TXNPI 1134459514
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 71.5% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2021 at $45,709 and has fallen 51.8% since, to $22,052 in 2025. Among interventional cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 697 payments — averaging $312.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$156K
- Cardiovascular Systems Inc.$33K
- Inari Medical, Inc.$9K
- Veryan Medical Incorporated$7K
- Reflow Medical Inc$4K
- Abbott$2K
- plus $9K from 38 others
Across 20 payments — averaging $5695.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vesper Medical$49K
- M.a. Med Alliance S.A.$25K
- Philips North America LLC$22K
- Veryan Medical Incorporated$13K
- Angiodynamics, Inc.$5K
What the payments were for
- Consulting fees$98,00045%
- Speaking & faculty fees$45,12521%
- Travel & lodging$8,0734%
- Food & beverage$38,57518%
- Education$15,0007%
- Other$12,9176%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$124,117
- Coronary Orbital Atherectomy System$23,397
- AngioVac$13,131
- FLOWTRIEVER CATHETER, S$8,625
- CT THROMBECTOMY SYSTEM KIT$8,625
- Peripheral Orbital Atherectomy System$7,741
- BioMimics 3D Vascular Stent System$4,750
- AlphaVac$893
- Ensite Cardiac Mapping System$711
- PANTHERIS$346
- Omnilink Elite vascular stent system$280
- BioMimics$259
- Carto 3$254
- Torus Stent Graft System$249
- ENDOCROSS Device$249
- PuraPly$248
- Diamondback Coronary$241
- Vesper Duo Venous Stent System$200
- ASAHI PTCA Guide Wire$155
- FLEX Scoring Catheter$150
How this compares
$217,689 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 252 | $191,328 |
| Repatha SureclickEvolocumab | 38 | $28,877 |
| EliquisApixaban | 21 | $28,255 |
| BrilintaTicagrelor | 11 | $13,820 |
| MultaqDronedarone Hcl | 11 | $8,396 |
| Prasugrel Hcl | 153 | $6,419 |
| ClopidogrelClopidogrel Bisulfate | 512 | $4,382 |
| Metoprolol Succinate | 86 | $1,404 |
| Nifedipine ErNifedipine | 33 | $1,086 |
| Amiodarone Hcl | 15 | $745 |
| Doxazosin Mesylate | 28 | $712 |
| Atorvastatin Calcium | 61 | $399 |
| Ezetimibe | 11 | $383 |
| Carvedilol | 31 | $379 |
| Lisinopril | 47 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $341 | $191,328252 claims |
| AstraZenecaBrilinta | $47 | $13,82011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Seguin
- Jonathan BonillaSeguin$154K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- Jeffrey CarrTyler$1.9M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.